Q-omics provides the consensus-scored CDKN1B profile across patient tissues and cancer cell-line models. CDKN1B expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CDKN1B is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, CDKN1B protein abundance shows 23,522 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight KIRC, and LUAD as cancer lineages where CDKN1B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CDKN1B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CDKN1B survival associations across molecular data types. CDKN1B RNA expression shows survival associations in the most cancer types (26), followed by mutation status (7) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CDKN1B RNA expression–survival associations across cancer types. High CDKN1B expression shows unfavorable associations in OV, but favorable associations in KIRC, SKCM, HNSC, READ and COAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CDKN1B RNA expression.
This table summarizes CDKN1B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 8. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for CDKN1B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CDKN1B shows lower tumor expression in THCA, UCEC, KICH and LUAD and higher tumor expression in KIRC and COAD. The KIRC box plot shows higher CDKN1B RNA expression in tumor versus normal tissue (log2 FC = +0.703, t-test p < 0.001).
This table shows molecular features associated with CDKN1B in patient tissues and cancer cell lines. In patient samples, CDKN1B shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, CDKN1B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in STOMACH, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and LUNG_SCLC.
